Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Elsevier to Work with Heel for Mechanism-based Drug Action Discovery
Posted on January 6th, 2021 by Thea Howe
Pharma R&D
Elsevier, the data analytics business specialized in science and health, and Heel, a pharmaceutical company specialized in developing and manufacturing medicines made from natural ingredients, have recently completed a series of research projects with a focus on improving exploratory preclinical studies.
(more…)The 10th Anniversary Reaxys PhD Prize Symposium: A Virtual Success
Posted on December 21st, 2020 by Ann-Marie Roche
Chemistry
No one anticipated that the 10th anniversary Reaxys PhD Prize Symposium would be a virtual event, but as we discussed earlier on in this blog, most gatherings of scientific researchers have had to go online this year because of COVID-19. As it turned out, the virtual symposium was a very special event in its own right.
(more…)Looking at Emerging Trends in Telemedicine
Posted on December 17th, 2020 by Thea Howe
Pharma R&D
Telemedicine, once an intriguing proposition struggling to reach its potential, became an absolute necessity in 2020. In the early days of COVID-19, as medical centers labored to deal with an influx of patients while also trying to mitigate coronavirus spread, telemedicine was urgently needed as an option for providing healthcare to others at a safe distance. In the U.S., the government and providers quickly started to take measures to facilitate its use during the crisis of the pandemic.
(more…)3D Printing Makes Medical Devices More Personal
Posted on December 10th, 2020 by Xuanyan Xu
Pharma R&D
Personalized medicine is a major trend in pharmaceutical R&D—and it’s transforming the way we think of therapeutics. Unlocking the secrets of the genome has made it possible to create treatments for disease that are more suited to the individual. But personalized medicine isn’t a concept that only applies to drug therapies. It is also highly relevant in the area of medical devices.
(more…)Pharma Industry Conferences Have Gone Online – Will They Stay There?
Posted on December 3rd, 2020 by Xuanyan Xu
Pharma R&D
Back in 2014, writer Nick de Cent posed the question Is it time for the conference to go virtual? He interviewed digital healthcare consultant Len Starnes, who argued that bringing pharma and healthcare conferences online could be beneficial in many ways, most notably in expanding participation. Six years later, and COVID-19 forced the issue, prompting many conferences to go fully virtual.
(more…)Interview with Greg Landrum at Elsevier: What are the ingredients of a successful Open Source cheminformatics software?
Posted on November 30th, 2020 by Elena Herzog
Chemistry
(Written by Elena Herzog in collaboration with Markus Fischer, Gerd Blanke, Jarek Tomczac and Gabrielle Whittick)
RDKit, a collection of cheminformatics and machine learning software, is assisting in solving chemical information challenges. The founder and creator of RDKit, Greg Landrum, was interviewed by the UDM (Unified Data Model) team, facilitated by Elsevier, to share his experience on what the road to success looks like and what ingredients does an open source project need to have to be successful. The learnings from the interview would help to shape the future of the UDM project, which is transferring from its consortium-led Pistoia Alliance model to a community-led model.
(more…)About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.
